Gaucher disease with parkinsonian manifestations: doe contribute to a vulnerability to parkinsonism?

Molecular Genetics and Metabolism

79, 104-109

DOI: 10.1016/s1096-7192(03)00071-4

Citation Report

#	Article	IF	Citations
1	Aberrant Phosphorylation of Î±-Synuclein in Human Niemann-Pick Type C1 Disease. Journal of Neuropathology and Experimental Neurology, 2004, 63, 323-328.	0.9	88
2	Parkinsonism among Gaucher disease carriers. Journal of Medical Genetics, 2004, 41, 937-940.	1.5	320
3	Glucocerebrosidase mutations in subjects with parkinsonism. Molecular Genetics and Metabolism, 2004, 81, 70-73.	0.5	353
4	Neuropathology provides clues to the pathophysiology of Gaucher disease. Molecular Genetics and Metabolism, 2004, 82, 192-207.	0.5	405
5	Global gene expression in a type 2 Gaucher disease brain. Molecular Genetics and Metabolism, 2004, 83, 288-296.	0.5	17
6	Gaucher disease: complexity in a â€œsimpleâ€•disorder. Molecular Genetics and Metabolism, 2004, 83, 6-15.	0.5	350
7	Therapeutic goals in the treatment of Gaucher disease. Seminars in Hematology, 2004, 41, 4-14.	1.8	418
8	Pilot association study of the Î²-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity. Movement Disorders, 2005, 20, 100-103.	2.2	93
9	Divergent phenotypes in Gaucher disease implicate the role of modifiers. Journal of Medical Genetics, 2005, 42, e37-e37.	1.5	100
10	Neurological Manifestations in Lysosomal Storage Disorders - From Pathology to First Therapeutic Possibilities. Neuropediatrics, 2005, 36, 285-289.	0.3	31
11	Gaucher disease and parkinsonism. Molecular Genetics and Metabolism, 2005, 84, 302-304.	0.5	75
12	Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology, 2006, 67, 908-910.	1.5	204
14	Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells, Molecules, and Diseases, 2006, 36, 426-428.	0.6	118
15	Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism. Neuroscience Letters, 2006, 404, 163-165.	1.0	14
16	A questionnaire study for 128 patients with Gaucher disease. Clinical Genetics, 2006, 69, 209-217.	1.0	18
17	Heterozygosity for a Mendelian disorder as a risk factor for complex disease. Clinical Genetics, 2006, 70, 275-282.	1.0	53
18	Primate segmental duplications: crucibles of evolution, diversity and disease. Nature Reviews Genetics, 2006, 7, 552-564.	7.7	498
19	Glucosylceramide transfer from lysosomesâ€”the missing link in molecular pathology of glucosylceramidase deficiency: A hypothesis based on existing data. Journal of Inherited Metabolic Disease, 2006, 29, 707-715.	1.7	39

#	Article	IF	Citations
20	Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Movement Disorders, 2006, 21, 282-283.	2.2	64
21	Self-stimulatory behavior associated with deep brain stimulation in Parkinson's disease. Movement Disorders, 2006, 21, 283-285.	2.2	34
22	Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology, 2006, 66, 415-417.	1.5	96
23	Gaucher Disease and the Synucleinopathies. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-6.	3.0	45
24	Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology, 2007, 69, 1270-1277.	1.5	226
25	Therapeutic Goals in the Treatment of Gaucher Disease. , 2007, , 345-370.		0
26	Chapter 8 Î±-Synuclein and Synucleinopathies. Blue Books of Neurology, 2007, 30, 186-215.	0.1	4
27	Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Molecular Genetics and Metabolism, 2007, 91, 195-200.	0.5	111
28	Lysosomal Storage Disorders. , 2007, , .		12
29	Treating Neurodegeneration by Modifying Mitochondria: Potential Solutions to a â€œComplexâ€•Problem. Antioxidants and Redox Signaling, 2007, 9, 1591-1604.	2.5	68
30	Parkinsonism and dystonia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 84, 507-529.	1.0	1
31	Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier. Journal of the Neurological Sciences, 2007, 252, 181-184.	0.3	33
32	Therapy Insight: inborn errors of metabolism in adult neurologyâ€”a clinical approach focused on treatable diseases. Nature Clinical Practice Neurology, 2007, 3, 279-290.	2.7	45
33	Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress. Journal of Cellular Physiology, 2007, 212, 223-235.	2.0	42
34	Movement and mood disorder in two brothers with Gaucher disease. Clinical Genetics, 2007, 72, 357-361.	1.0	10
35	â€˜Nonâ€neuronopathicâ€™ Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. Journal of Inherited Metabolic Disease, 2008, 31, 337-349.	1.7	79
36	Movement disorders and inborn errors of metabolism in adults: A diagnostic approach. Journal of Inherited Metabolic Disease, 2008, 31, 308-318.	1.7	79
37	Glucocerebrosidase gene mutations are associated with Parkinson's disease in southern Italy. Movement Disorders, 2008, 23, 460-463.	2.2	83

#	Article	IF	Citations
39	Treating patients with Gaucher disease and parkinsonism: Misrepresentation in a title. Parkinsonism and Related Disorders, 2008, 14, 81-82.	1.1	3
40	Association between Parkinson's disease and glucocerebrosidase mutations in Brazil. Parkinsonism and Related Disorders, 2008, 14, 58-62.	1.1	62
41	Glucocerebrosidase Gene Mutations. Archives of Neurology, 2008, 65, 379-82.	4.9	188
42	The Spectrum of Parkinsonian Manifestations Associated With Glucocerebrosidase Mutations. Archives of Neurology, 2008, 65, 1353-7.	4.9	170
43	Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology, 2008, 70, 2277-2283.	1.5	334
44	Progress in the pathogenesis and genetics of Parkinson's disease. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 2215-2227.	1.8	63
45	A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica, 2008, 93, 1211-1218.	1.7	55
47	Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain, 2009, 132, 1783-1794.	3.7	612
48	MUTATIONS IN GBA ARE ASSOCIATED WITH FAMILIAL PARKINSON DISEASE SUSCEPTIBILITY AND AGE AT ONSET. Neurology, 2009, 73, 1424-1426.	1.5	142
49	The Expanding Role of Genetics in the Lewy Body Diseases. Archives of Neurology, 2009, 66, 555-6.	4.9	5
50	Cerebrospinal fluid Î²-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. Neurobiology of Disease, 2009, 34, 484-486.	2.1	61
51	No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Movement Disorders, 2009, 24, 1519-1523.	2.2	72
52	The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism. Movement Disorders, 2009, 24, 1571-1578.	2.2	71
53	Parkinsonism in Gaucher's disease type 1: Ten new cases and a review of the literature. Movement Disorders, 2009, 24, 1524-1530.	2.2	28
54	Bell's palsy preceding Parkinson's disease: A caseâ€control study. Movement Disorders, 2009, 24, 1530-1533.	2.2	1
55	Vertical optokinetic nystagmus in Parkinson's disease. Movement Disorders, 2009, 24, 1533-1538.	2.2	4
56	Deep brain stimulation in dystonia: Sonographic monitoring of electrode placement into the globus pallidus internus. Movement Disorders, 2009, 24, 1538-1541.	2.2	22
57	Tremor on smiling. Movement Disorders, 2009, 24, 1542-1545.	2.2	9

#	Article	IF	Citations
58	Pathogenic cascades in lysosomal diseaseâ€"Why so complex?. Journal of Inherited Metabolic Disease, 2009, 32, 181-189.	1.7	115
59	Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent. Immunology and Cell Biology, 2009, 87, 514-524.	1.0	30
60	Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease. New England Journal of Medicine, 2009, 361, 1651-1661.	13.9	1,747
61	Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology, 2009, 72, 310-316.	1.5	215
62	Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neuroscience Letters, 2009, 452, 87-89.	1.0	94
63	Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: A biological link between Gaucher disease and parkinsonism. NeuroToxicology, 2009, 30, 1127-1132.	1.4	164
65	Glucocerebrosidase as a genetic modifier influencing susceptibility and phenotype of Parkinsonâ€™s disease. Future Neurology, 2010, 5, 189-193.	0.9	0
66	Microarray analysis of differentially expressed genes in vaginal tissues in postmenopausal women. The role of stress urinary incontinence. International Urogynecology Journal, 2010, 21, 1545-1551.	0.7	5
67	Glucocerebrosidase is present in Î±-synuclein inclusions in Lewy body disorders. Acta Neuropathologica, 2010, 120, 641-649.	3.9	169
68	Glucocerebrosidase mutations p.L444P and p.N370S are not associated with multisystem atrophy, progressive supranuclear palsy and corticobasal degeneration in Polish patients. Journal of Neurology, 2010, 257, 459-460.	1.8	24
69	Deregulated Sphingolipid Metabolism and Membrane Organization in Neurodegenerative Disorders. Molecular Neurobiology, 2010, 41, 314-340.	1.9	117
70	The Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders. Current Neurology and Neuroscience Reports, 2010, 10, 190-198.	2.0	131
71	The risk of Parkinson's disease in type 1 Gaucher disease. Journal of Inherited Metabolic Disease, 2010, 33, 167-173.	1.7	182
72	The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). Journal of Inherited Metabolic Disease, 2010, 33, 331-338.	1.7	63
73	Transient amantadine-induced musical hallucinations in a patient with Parkinson's disease. Movement Disorders, 2010, 25, 1505-1506.	2.2	12
74	Gaucher disease ascertained through a Parkinson's center: Imaging and clinical characterization. Movement Disorders, 2010, 25, 1364-1372.	2.2	77
75	Atypical parkinsonism with apraxia and supranuclear gaze abnormalities in type 1 Gaucher disease. Expanding the spectrum: Case report and literature review. Movement Disorders, 2010, 25, 1506-1509.	2.2	21
76	Rare and serious cardiac side effects during ropinirole titration. Movement Disorders, 2010, 25, 1509-1510.	2.2	8

#	Article	IF	Citations
77	Valproateâ€induced reversible hemichorea. Movement Disorders, 2010, 25, 1511-1512.	2.2	15
78	Facial tic associated with lamotrigine in adults. Movement Disorders, 2010, 25, 1512-1513.	2.2	10
79	Primary progressive freezing gait in a patient with COâ€induced parkinsonism. Movement Disorders, 2010, 25, 1513-1515.	2.2	14
80	Multiple system atrophy and colon inertia. Movement Disorders, 2010, 25, 1515-1516.	2.2	0
81	Multipleâ€system atrophy presenting with low rectal compliance and bowel pain. Movement Disorders, 2010, 25, 1516-1518.	2.2	3
82	Changes in apraxia after deep brain stimulation of the nucleus basalis Meynert in a patient with Parkinson dementia syndrome. Movement Disorders, 2010, 25, 1519-1520.	2.2	43
83	Congenital mirror movements in Parkinson's disease: Clinical and neurophysiological observations. Movement Disorders, 2010, 25, 1520-1523.	2.2	6
84	Parkinsonism and cognitive decline in a fragile X mosaic male. Movement Disorders, 2010, 25, 1523-1524.	2.2	12
85	Olfactory dysfunction in Japanese patients with idiopathic REM sleep behavior disorder: Comparison of data using the university of Pennsylvania smell identification test and odor stick identification test for Japanese. Movement Disorders, 2010, 25, 1524-1526.	2.2	11
86	Functional brain imaging in glucocerebrosidase mutation carriers with and without Parkinsonism. Movement Disorders, 2010, 25, 1823-1829.	2.2	42
87	Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease. Human Molecular Genetics, 2010, 19, 3771-3781.	1.4	93
88	Association between GBA L444P mutation and sporadic Parkinson's disease from Mainland China. Neuroscience Letters, 2010, 469, 256-259.	1.0	56
90	Gaucher Disease Glucocerebrosidase and Î±-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies. Cell, 2011, 146, 37-52.	13.5	1,097
91	Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells, Molecules, and Diseases, 2011, 46, 4-10.	0.6	91
92	Accumulation and distribution of Î±-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Molecular Genetics and Metabolism, 2011, 102, 436-447.	0.5	130
93	Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. Molecular Genetics and Metabolism, 2011, 103, 410-412.	0.5	40
94	Aggregation of Î±-synuclein in brain samples from subjects with glucocerebrosidase mutations. Molecular Genetics and Metabolism, 2011, 104, 185-188.	0.5	67
97	Prevalence and management of Gaucher disease. Pediatric Health, Medicine and Therapeutics, 2011, , 59.	0.7	3

#	Article	IF	Citations
98	Neurological manifestations in patients with Gaucher disease and their relatives, it is just a coincidence?. Journal of Inherited Metabolic Disease, 2011, 34, 781-787.	1.7	17
99	Decades of delayed diagnosis in 4 levodopaâ€responsive youngâ€onset monogenetic parkinsonism patients. Movement Disorders, 2011, 26, 1337-1340.	2.2	4
100	Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. Movement Disorders, 2011, 26, 1348-1352.	2.2	18
101	Osteopontin polymorphic susceptibility factor for Parkinson's disease among patients with Gaucher disease. Movement Disorders, 2011, 26, 1341-1343.	2.2	6
102	Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease. Movement Disorders, 2011, 26, 1344-1347.	2.2	17
103	Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Movement Disorders, 2011, 26, 1593-1604.	2.2	141
104	Pathological looping in the synucleinopathies: investigating the link between Parkinsonâ€™s disease and Gaucher disease. DMM Disease Models and Mechanisms, 2011, 4, 713-715.	1.2	13
105	A Twelve-Year Follow-Up Study on a Case of Early-Onset Parkinsonism Preceding Clinical Manifestation of Gaucher Disease. JIMD Reports, 2011, 3, 53-57.	0.7	4
106	Î±-Synuclein Interacts with Glucocerebrosidase Providing a Molecular Link between Parkinson and Gaucher Diseases. Journal of Biological Chemistry, 2011, 286, 28080-28088.	1.6	160
107	CNS expression of glucocerebrosidase corrects Î±-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12101-12106.	3.3	282
108	The link between the GBA gene and parkinsonism. Lancet Neurology, The, 2012, 11, 986-998.	4.9	475
109	Mutant <i>GBA1</i> Expression and Synucleinopathy Risk: First Insights from Cellular and Mouse Models. Neurodegenerative Diseases, 2012, 10, 195-202.	0.8	26
110	Glucocerebrosidase gene variants in parkinsonian patients with Machado Joseph/spinocerebellar ataxia 3. Parkinsonism and Related Disorders, 2012, 18, 185-190.	1.1	17
111	Association of mutations in the glucocerebrosidase gene with Parkinson disease in a Korean population. Neuroscience Letters, 2012, 514, 12-15.	1.0	49
112	Genetics and Epigenetics of Parkinson's Disease. Scientific World Journal, The, 2012, 2012, 1-12.	0.8	148
113	Glucocerebrosidase Involvement in Parkinson Disease and Other Synucleinopathies. Frontiers in Neurology, 2012, 3, 65.	1.1	15
114	The neuropathology of genetic Parkinson's disease. Movement Disorders, 2012, 27, 831-842.	2.2	229
115	The genetics and neuropathology of Parkinsonâ€™s disease. Acta Neuropathologica, 2012, 124, 325-338.	3.9	281

#	Article	IF	Citations
116	Molecular pathogenesis of Parkinson's disease: update. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 430-436.	0.9	69
117	The Association Between ÃŸ-Glucocerebrosidase Mutations and Parkinsonism. Current Neurology and Neuroscience Reports, 2013, 13, 368.	2.0	32
118	Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Diseaseâ€"Links to Parkinsonâ€™s Disease. Cell Metabolism, 2013, 17, 941-953.	7.2	277
120	Sphingolipids in Disease. Handbook of Experimental Pharmacology, 2013, , .	0.9	7
121	Clinical, genetic, and brain sonographic features related to Parkinsonâ€™s disease in Gaucher disease. Journal of Neurology, 2013, 260, 2523-2531.	1.8	16
122	Increased incidence of Parkinsonism among Chinese with Î²-glucosidase mutation in central Taiwan.		

#	Article	IF	Citations
137	Development of targeted therapies for Parkinson's disease and related synucleinopathies. Journal of Lipid Research, 2014, 55, 1996-2003.	2.0	17
138	Recent advances in Parkinsonâ€™s disease genetics. Journal of Neurology, 2014, 261, 259-266.	1.8	65
139	Advances in the Genetics of Parkinson's Disease: A Guide for the Clinician. Movement Disorders Clinical Practice, 2014, 1, 3-13.	0.8	17
140	Glucocerebrosidase is shaking up the synucleinopathies. Brain, 2014, 137, 1304-1322.	3.7	128
141	Î±-Synuclein rs356219 polymorphisms in patients with Gaucher disease and Parkinson disease. Neuroscience Letters, 2014, 580, 104-107.	1.0	2
142	Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications. Orphanet Journal of Rare Diseases, 2014, 9, 112.	1.2	34
143	Arylsulphatase A activity in familial parkinsonism: a pathogenetic role?. Journal of Neurology, 2014, 261, 1803-1809.	1.8	8
144	The significance of GBA for Parkinson's disease. Journal of Inherited Metabolic Disease, 2014, 37, 643-648.	1.7	36
145	Studies of glucocerebrosidase provide new therapeutic targets for parkinsonism. Future Neurology, 2014, 9, 407-409.	0.9	0
146	Sphingolipid lysosomal storage disorders. Nature, 2014, 510, 68-75.	13.7	270
147	Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Human Molecular Genetics, 2014, 23, 3943-3957.	1.4	79
148	Gaucher Disease. , 2015, , 301-311.		0
149	Genetics Underlying Atypical Parkinsonism and Related Neurodegenerative Disorders. International Journal of Molecular Sciences, 2015, 16, 24629-24655.	1.8	21
150	Gene-Wise Association of Variants in Four Lysosomal Storage Disorder Genes in Neuropathologically Confirmed Lewy Body Disease. PLoS ONE, 2015, 10, e0125204.	1.1	52
151	GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder. Annals of Clinical and Translational Neurology, 2015, 2, 941-945.	1.7	117
152	Fluorescence-Quenched Substrates for Live Cell Imaging of Human Glucocerebrosidase Activity. Journal of the American Chemical Society, 2015, 137, 1181-1189.	6.6	59
153	Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends in Genetics, 2015, 31, 140-149.	2.9	193
154	Genetics of Parkinsonâ€™s Disease. , 2015, , 19-34.		3

#	Article	IF	Citations
155	Sustained Systemic Glucocerebrosidase Inhibition Induces Brain Î±-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice. Antioxidants and Redox Signaling, 2015, 23, 550-564.	2.5	118
156	Gaucher-Associated Parkinsonism. Cellular and Molecular Neurobiology, 2015, 35, 755-761.	1.7	22
157	Understanding and managing parkinsonism in patients with glucocerebrosidase mutations. Expert Opinion on Orphan Drugs, 2015, 3, 549-562.	0.5	1
159	Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant Î±-synuclein and aggravates neurodegeneration in aDrosophilamodel of Parkinson's disease. Human Molecular Genetics, 2015, 24, 6675-6686.	1.4	81
160	Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease. Neurobiology of Aging, 2015, 36, 3306-3313.	1.5	89
161	Genotypeâ€“Phenotype Correlations in Parkinson Disease. , 2015, , 259-285.		1
162	The emergence of Parkinson disease among patients with Gaucher disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 249-259.	2.2	12
164	<scp>N</scp>omenclature of genetic movement disorders: <scp>R</scp>ecommendations of the international <scp>P</scp>arkinson and movement disorder society task force. Movement Disorders, 2016, 31, 436-457.	2.2	228
165	The relationship between glucocerebrosidase mutations and Parkinson disease. Journal of Neurochemistry, 2016, 139, 77-90.	2.1	167
166	Clinical studies of GBA1-associated parkinsonism: progress and challenges. Neurodegenerative Disease Management, 2016, 6, 1-4.	1.2	4
167	Clinical course and prognosis in patients with Gaucher disease and parkinsonism. Neurology: Genetics, 2016, 2, e57.	0.9	29
168	Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. Expert Review of Proteomics, 2016, 13, 471-479.	1.3	51
169	Neuronopathic Gaucher Disease. Journal of Pediatric Biochemistry, 2016, 06, 039-045.	0.2	0
170	The contribution of mutantGBAto the development of Parkinson disease inDrosophila. Human Molecular Genetics, 2016, 25, ddw129.	1.4	60
171	The Lysosome as a Regulatory Hub. Annual Review of Cell and Developmental Biology, 2016, 32, 223-253.	4.0	412
172	Parkinson's disease: acidâ€glucocerebrosidase activity and alphaâ€synuclein clearance. Journal of Neurochemistry, 2016, 139, 198-215.	2.1	59
173	Genetics in Parkinson disease: Mendelian versus nonâ€Mendelian inheritance. Journal of Neurochemistry, 2016, 139, 59-74.	2.1	390
174	How can <scp>rAAV</scp>â€Î±â€synuclein and the fibril Î±â€synuclein models advance our understanding of Parkinson's disease?. Journal of Neurochemistry, 2016, 139, 131-155.	2.1	84

#	Article	IF	Citations
175	Glycobiology of Human Milk in Health and Disease. , 2016, , 233-250.		0
176	Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease. Movement Disorders, 2016, 31, 1610-1618.	2.2	47
177	A New Glucocerebrosidase Chaperone Reduces Â-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. Journal of Neuroscience, 2016, 36, 7441-7452.	1.7	189
178	The Link Between Lysosomal Storage Disorders and More Common Diseases. FIRE Forum for International Research in Education, 2016, 4, 232640981668276.	0.7	7
179	Lysosomal Dysfunction and Î±â€Synuclein Aggregation in Parkinson's Disease: Diagnostic Links. Movement Disorders, 2016, 31, 791-801.	2.2	125
180	Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance. American Journal of Physiology - Renal Physiology, 2016, 310, G1102-G1117.	1.6	53
181	GBA Mutations Are Associated With Earlier Onset and Male Sex in Dementia With Lewy Bodies. Movement Disorders, 2016, 31, 1066-1070.	2.2	34
182	The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. Drug Discovery Today, 2016, 21, 802-818.	3.2	247
183	What lysosomes actually tell us about Parkinsonâ€™s disease?. Ageing Research Reviews, 2016, 32, 140-149.	5.0	19
184	From rare to common and back again: 60years of lysosomal dysfunction. Molecular Genetics and Metabolism, 2016, 117, 53-65.	0.5	17
186	Genetics of Parkinson's Disease. International Review of Neurobiology, 2017, 132, 197-231.	0.9	76
187	Genetic Identification in Early Onset Parkinsonism among Norwegian Patients. Movement Disorders Clinical Practice, 2017, 4, 499-508.	0.8	25
188	Heterozygote galactocerebrosidase (GALC) mutants have reduced remyelination and impaired myelin debris clearance following demyelinating injury. Human Molecular Genetics, 2017, 26, 2825-2837.	1.4	27
189	Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinsonâ€™s disease. Expert Review of Molecular Diagnostics, 2017, 17, 771-780.	1.5	23
190	Insights into the structural biology of Gaucher disease. Experimental Neurology, 2017, 298, 180-190.	2.0	55
191	Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature. Movement Disorders, 2017, 32, 1504-1523.	2.2	229
192	Parkinsonâ€™s Disease: Basic Pathomechanisms and a Clinical Overview. Advances in Neurobiology, 2017, 15, 55-92.	1.3	2
193	Connecting Gaucher and Parkinson Disease: Considerations for Clinical and Research Genetic Counseling Settings. Journal of Genetic Counseling, 2017, 26, 1165-1172.	0.9	7

#	Article	IF	Citations
194	Gaucher disease: Progress and ongoing challenges. Molecular Genetics and Metabolism, 2017, 120, 8-21.	0.5	112
195	Excessive burden of lysosomal storage disorder gene variants in Parkinsonâ€™s disease. Brain, 2017, 140, 3191-3203.	3.7	323
196	Recent advances in the diagnosis and management of Gaucher disease. Expert Review of Endocrinology and Metabolism, 2018, 13, 107-118.	1.2	78
197	Features of GBA-associated Parkinsonâ€™s disease at presentation in the UK Tracking Parkinsonâ€™s study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 702-709.	0.9	103
198	Alpha-synucleinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 339-353.	1.0	50
199	Pathological role of lipid interaction with Î±-synuclein in Parkinson's disease. Neurochemistry International, 2018, 119, 97-106.	1.9	53
200	Type I Gaucher disease with bullous pemphigoid and Parkinson disease. Medicine (United States), 2018, 97, e0188.	0.4	2
201	Classifying the additional morbidities of Gaucher disease. Blood Cells, Molecules, and Diseases, 2018, 68, 209-210.	0.6	2
202	Glucocerebrosidase mutations and parkinsonism: how much does the mutation matter?. Journal of Xiangya Medicine, 0, 3, 1-1.	0.2	3
203	Parkinsonism in Inherited Metabolic Disorders: Key Considerations and Major Features. Frontiers in Neurology, 2018, 9, 857.	1.1	15
204	High-frequency actionable pathogenic exome variants in an average-risk cohort. Journal of Physical Education and Sports Management, 2018, 4, a003178.	0.5	23
205	Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum. Molecular Genetics and Metabolism Reports, 2018, 17, 69-72.	0.4	4
206	Self-report data as a tool for subtype identification in genetically-defined Parkinsonâ€™s Disease. Scientific Reports, 2018, 8, 12992.	1.6	12
207	Common and Founder Mutations for Monogenic Traits in Sub-Saharan African Populations. Annual Review of Genomics and Human Genetics, 2018, 19, 149-175.	2.5	9
208	Fluorescence-Quenched Substrates for Quantitative Live Cell Imaging of Glucocerebrosidase Activity. Methods in Enzymology, 2018, 598, 199-215.	0.4	5
209	Computational modelling approaches as a potential platform to understand the molecular genetics association between Parkinsonâ€™s and Gaucher diseases. Metabolic Brain Disease, 2018, 33, 1835-1847.	1.4	31
210	Î±-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Molecular Neurodegeneration, 2018, 13, 1.	4.4	143
211	Dermal fibroblasts from patients with Parkinsonâ€™s disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations. F1000Research, 2017, 6, 1751.	0.8	8

#	Article	IF	Citations
212	The motor and cognitive features of Parkinsonâ€™s disease in patients with concurrent Gaucher disease over 2 years: a case series. Journal of Neurology, 2018, 265, 1789-1794.	1.8	11
213	Lysosome biogenesis in health and disease. Journal of Neurochemistry, 2019, 148, 573-589.	2.1	97
214	Lipids as Trans-Acting Effectors for Î±-Synuclein in the Pathogenesis of Parkinsonâ€™s Disease. Frontiers in Neuroscience, 2019, 13, 693.	1.4	15
215	Trends in Glycolipid Biomarker Discovery in Neurodegenerative Disorders by Mass Spectrometry. Advances in Experimental Medicine and Biology, 2019, 1140, 703-729.	0.8	13
216	Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2019, 14, 40.	4.4	100
217	The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2019, 20, 5312.	1.8	78
218	Glucocerebrosidase and its relevance to Parkinson disease. Molecular Neurodegeneration, 2019, 14, 36.	4.4	197
219	Insights into GBA Parkinson's disease pathology and therapy with induced pluripotent stem cell model systems. Neurobiology of Disease, 2019, 127, 1-12.	2.1	13
220	Viral delivery of a microRNA to Gba to the mouse central nervous system models neuronopathic Gaucher disease. Neurobiology of Disease, 2019, 130, 104513.	2.1	9
221	GBA, Gaucher Disease, and Parkinsonâ€™s Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells, 2019, 8, 364.	1.8	187
222	Emerging therapies in Parkinson disease â€” repurposed drugs and new approaches. Nature Reviews Neurology, 2019, 15, 204-223.	4.9	189
223	Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies. Clinica Chimica Acta, 2019, 495, 13-24.	0.5	18
224	Genetic mimics of the non-genetic atypical parkinsonian disorders â€“ the â€˜atypicalâ€™ atypical. International Review of Neurobiology, 2019, 149, 327-351.	0.9	8
225	Autophagic and endo-lysosomal dysfunction in neurodegenerative disease. Molecular Brain, 2019, 12, 100.	1.3	122
226	Novel Small Molecule Shows Promise in Familial Form of Parkinson's Disease. Neurology Today: an Official Publication of the American Academy of Neurology, 2019, 19, 18-19.	0.0	0
227	Path mediation analysis reveals GBA impacts Lewy body disease status by increasing Î±-synuclein levels. Neurobiology of Disease, 2019, 121, 205-213.	2.1	43
228	Single-Cell Sequencing of iPSC-Dopamine Neurons Reconstructs Disease Progression and Identifies HDAC4 as a Regulator of Parkinson Cell Phenotypes. Cell Stem Cell, 2019, 24, 93-106.e6.	5.2	123
229	Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy. Journal of Inherited Metabolic Disease, 2020, 43, 564-573.	1.7	4

#	Article	IF	Citations
230	Parkinsonâ€™s Disease and Fabry Disease: Clinical, Biochemical and Neuroimaging Analysis of Three Pedigrees. Journal of Parkinson's Disease, 2020, 10, 141-152.	1.5	14
231	Clinical Evaluation of Sibling Pairs With Gaucher Disease Discordant for Parkinsonism. Movement Disorders, 2020, 35, 359-365.	2.2	10
232	Parkinsonâ€™s disease in Gaucher disease patients: whatâ€™s changing in the counseling and management of patients and their relatives?. Orphanet Journal of Rare Diseases, 2020, 15, 262.	1.2	3
233	Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review. International Journal of Molecular Sciences, 2020, 21, 7159.	1.8	56
234	Cell type-specific lipid storage changes in Parkinsonâ€™s disease patient brains are recapitulated by experimental glycolipid disturbance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27646-27654.	3.3	59
235	Glycosphingolipids and neuroinflammation in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2020, 15, 59.	4.4	78
236	Trends in Glucocerebrosides Research: A Systematic Review. Frontiers in Physiology, 2020, 11, 558090.	1.3	2
237	Neurodegeneration and Inflammationâ€”An Interesting Interplay in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 8421.	1.8	160
238	Human breast milk as source of sphingolipids for newborns: comparison with infant formulas and commercial cowâ€™s milk. Journal of Translational Medicine, 2020, 18, 481.	1.8	18
239	Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinsonâ€™s disease pathogenesis. Acta Neuropathologica Communications, 2020, 8, 63.	2.4	45
240	Mutated ATP10B increases Parkinsonâ€™s disease risk by compromising lysosomal glucosylceramide export. Acta Neuropathologica, 2020, 139, 1001-1024.	3.9	46
241	Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease. CNS Drugs, 2020, 34, 915-923.	2.7	14
242	Lysosome and Inflammatory Defects in GBA1â€Mutant Astrocytes Are Normalized by LRRK2 Inhibition. Movement Disorders, 2020, 35, 760-773.	2.2	79
243	Lysosomal Ceramide Metabolism Disorders: Implications in Parkinsonâ€™s Disease. Journal of Clinical Medicine, 2020, 9, 594.	1.0	31
244	Glucocerebrosidase as a therapeutic target for Parkinsonâ€™s disease. Expert Opinion on Therapeutic Targets, 2020, 24, 287-294.	1.5	19
245	The biochemical basis of interactions between Glucocerebrosidase and alphaâ€synuclein in GBA1 mutation carriers. Journal of Neurochemistry, 2020, 154, 11-24.	2.1	10
246	Pathways of protein synthesis and degradation in PD pathogenesis. Progress in Brain Research, 2020, 252, 217-270.	0.9	5
247	Cross-talks among GBA mutations, glucocerebrosidase, and Î±-synuclein in GBA-associated Parkinsonâ€™s disease and their targeted therapeutic approaches: a comprehensive review. Translational Neurodegeneration, 2021, 10, 4.	3.6	48

#	Article	IF	Citations
248	Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease. Movement Disorders, 2021, 36, 1451-1455.	2.2	17
249	Therapeutic Potential of Î±S Evolvability for Neuropathic Gaucher Disease. Biomolecules, 2021, 11, 289.	1.8	4
250	Novel targeted therapies for Parkinsonâ€™s disease. Molecular Medicine, 2021, 27, 17.	1.9	54
251	Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia. NeuroMolecular Medicine, 2021, 23, 1-24.	1.8	9
252	Complement cascade functions during brain development and neurodegeneration. FEBS Journal, 2022, 289, 2085-2109.	2.2	19
253	Murine Models of Lysosomal Storage Diseases Exhibit Differences in Brain Protein Aggregation and Neuroinflammation. Biomedicines, 2021, 9, 446.	1.4	12
255	Impact of Gba2 on neuronopathic Gaucherâ€™s disease and Î±-synuclein accumulation in medaka (Oryzias) Tj ETQq0 0 0 rgBT /Overloc	1.3	3
256	â€œJanus-Facedâ€•Î±-Synuclein: Role in Parkinsonâ€™s Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 673395.	1.8	8
257	Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinsonâ€™s disease patients. Journal of Neurology, 2022, 269, 1485-1500.	1.8	24
259	Glucocerebrosidase dysfunction in neurodegenerative disease. Essays in Biochemistry, 2021, 65, 873-883.	2.1	4
260	A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy. Neurobiology of Disease, 2021, 159, 105507.	2.1	14
261	Complexity of Genotype-Phenotype Correlations in Mendelian Disorders: Lessons from Gaucher Disease. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 69-90.	0.6	5
262	Modeling of Human Parkinsonâ€™s Disease in Fly. , 2019, , 279-310.		1
263	Altered lipid metabolic homeostasis in the pathogenesis of Alzheimerâ€™s disease. , 2020, , 469-504.		5
264	Nonneoplastic Histiocytic Proliferations of Lymph Nodes and Bone Marrow. , 2011, , 801-810.		1
265	Lysosomal diseases. , 2008, , 515-599.		2
266	Dermal fibroblasts from patients with Parkinsonâ€™s disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations. F1000Research, 2017, 6, 1751.	0.8	8
267	Pathological Mechanisms and Clinical Aspects of GBA1 Mutation-Associated Parkinsonâ€™s Disease. , 0, , 45-64.		5

#	Article	IF	Citations
268	Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with <scp>GBA</scp> Mutations. Movement Disorders, 2022, 37, 106-118.	2.2	13
269	The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease. Neurodegenerative Disease Management, 2021, 11, 451-458.	1.2	7
270	Iron Overload in Gaucher Cells and Bone Marrow that Is Not Associated with Hemochromatosis Gene Mutations C282Y and H63D in a Patient Having Coexistent Gaucher and Parkinsonâ€™s Disease. Hungarian Medical Journal, 2007, 1, 371-374.	0.0	0
271	CFS Biomarkers in Parkinsonâ€™s Disease. , 0, , .		0
272	Role of Lysosomal Enzymes in Parkinsonâ€™s Disease: Lesson from Gaucherâ€™s Disease. , 0, , .		0
273	Advances in the Genetics of Human Tremor. , 2013, , 53-78.		0
275	Genetics of Atypical Parkinsonism. , 2015, , 35-64.		0
278	Linking glucocerebrosidase gene (GBA) variants and Parkinson's disease. , 2020, , 67-81.		1
279	Gaucher diseaseâ€"neuronopathic forms. , 2020, , 439-449.		0
280	Gaucher disease: insights from a rare Mendelian disorder. Discovery Medicine, 2012, 14, 273-81.	0.5	80
281	Glycosphingolipids. Advances in Experimental Medicine and Biology, 2021, 1325, 61-102.	0.8	11
282	LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease. Translational Neurodegeneration, 2022, 11, 5.	3.6	21
283	Impaired Sphingolipid Hydrolase Activities in Dementia with Lewy Bodies and Multiple System Atrophy. Molecular Neurobiology, 2022, 59, 2277-2287.	1.9	7
284	Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus. Molecular Genetics and Metabolism, 2022, 135, 154-162.	0.5	10
285	Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinsonâ€™s Disease: Pathogenesis and Therapeutic Implications. Frontiers in Aging Neuroscience, 2022, 14, 851135.	1.7	7
286	Recombinant pro-CTSD (cathepsin D) enhances SNCA/Î±-Synuclein degradation in Î±-Synucleinopathy models. Autophagy, 2022, 18, 1127-1151.	4.3	20
287	GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells, 2022, 11, 1261.	1.8	61
288	Parkinson's disease and the spectrum of Lewy body disease. , 0, , 10-26.		0

#	Article	IF	Citations
289	Synucleinopathies. , 2014, , 149-175.		0
291	Lipid pathway dysfunction is prevalent in patients with Parkinsonâ€™s disease. Brain, 2022, 145, 3472-3487.	3.7	25
292	Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism. International Journal of Molecular Sciences, 2022, 23, 5842.	1.8	8
293	Glucocerebrosidase mutations and Parkinson disease. Journal of Neural Transmission, 2022, 129, 1105-1117.	1.4	19
294	Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease. Frontiers in Neurology, 0, 13, .	1.1	7
295	Neurodegeneration and inflammation crosstalk: Therapeutic targets and perspectives. IBRO Neuroscience Reports, 2023, 14, 95-110.	0.7	7
296	Mechanisms of Glucocerebrosidase Dysfunction in Parkinsonâ€™s Disease. Journal of Molecular Biology, 2023, 435, 168023.	2.0	7
297	Genetic Evidence for Endolysosomal Dysfunction in Parkinsonâ€™s Disease: A Critical Overview. International Journal of Molecular Sciences, 2023, 24, 6338.	1.8	2
304	Advances in the Genetics of Human Tremor. Contemporary Clinical Neuroscience, 2023, , 43-74.	0.3	0